KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 72 filers reported holding KINNATE BIOPHARMA INC in Q1 2023. The put-call ratio across all filers is 0.27 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $110,559 | -77.1% | 78,971 | -50.3% | 0.00% | – |
| Q2 2023 | $481,785 | -64.9% | 159,005 | -27.6% | 0.00% | – |
| Q1 2023 | $1,371,981 | +212.2% | 219,517 | +204.7% | 0.00% | – |
| Q4 2022 | $439,432 | -81.6% | 72,038 | -63.9% | 0.00% | -100.0% |
| Q3 2022 | $2,387,000 | -10.3% | 199,788 | -5.3% | 0.00% | 0.0% |
| Q2 2022 | $2,660,000 | +246.8% | 210,958 | +209.5% | 0.00% | – |
| Q1 2022 | $767,000 | -24.2% | 68,154 | +19.4% | 0.00% | – |
| Q4 2021 | $1,012,000 | -53.5% | 57,067 | -39.7% | 0.00% | – |
| Q3 2021 | $2,177,000 | +515.0% | 94,561 | +521.6% | 0.00% | – |
| Q2 2021 | $354,000 | -36.1% | 15,212 | -14.4% | 0.00% | – |
| Q1 2021 | $554,000 | -76.9% | 17,774 | -70.5% | 0.00% | -100.0% |
| Q4 2020 | $2,398,000 | – | 60,286 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |